| 6.84 0.29 (4.43%) | 02-11 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 8.59 | 1-year : | 9.4 |
| Resists | First : | 7.35 | Second : | 8.05 |
| Pivot price | 6.6 |
|||
| Supports | First : | 6.23 | Second : | 5.18 |
| MAs | MA(5) : | 6.46 |
MA(20) : | 6.65 |
| MA(100) : | 7.16 |
MA(250) : | 8.1 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 36.2 |
D(3) : | 21.2 |
| RSI | RSI(14): 51.1 |
|||
| 52-week | High : | 11.31 | Low : | 6 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ BCRX ] has closed below upper band by 19.2%. Bollinger Bands are 19.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 6.91 - 6.94 | 6.94 - 6.97 |
| Low: | 6.4 - 6.43 | 6.43 - 6.45 |
| Close: | 6.79 - 6.84 | 6.84 - 6.89 |
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Wed, 11 Feb 2026
BioCryst Pharmaceuticals to Present Nine Abstracts on Hereditary Angioedema at 2026 AAAAI Annual Meeting - Quiver Quantitative
Wed, 11 Feb 2026
Shots every 3–6 months suppress HAE attacks in BioCryst trial data - Stock Titan
Sat, 07 Feb 2026
Jim Cramer on BioCryst Pharmaceuticals: "Just Stay Away From That" - Finviz
Sat, 07 Feb 2026
BioCryst Uses Equity Grants To Support Rare Disease Pipeline And Talent - Sahm
Sat, 07 Feb 2026
Jim Cramer on BioCryst Pharmaceuticals: “Just Stay Away From That” - Insider Monkey
Tue, 03 Feb 2026
BioCryst Pharmaceuticals, Inc. (BCRX) Investor Outlook: Exploring a Potential 226.80% Upside - DirectorsTalk Interviews
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 248 (M) |
| Shares Float | 195 (M) |
| Held by Insiders | 1.3 (%) |
| Held by Institutions | 84.9 (%) |
| Shares Short | 43,200 (K) |
| Shares Short P.Month | 36,010 (K) |
| EPS | -0.06 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -1.85 |
| Profit Margin | -1.5 % |
| Operating Margin | 18.5 % |
| Return on Assets (ttm) | 10.3 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 36 % |
| Gross Profit (p.s.) | 1.65 |
| Sales Per Share | 2.41 |
| EBITDA (p.s.) | 0.32 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 50 (M) |
| Levered Free Cash Flow | 63 (M) |
| PE Ratio | -136.81 |
| PEG Ratio | 0 |
| Price to Book value | -3.72 |
| Price to Sales | 2.82 |
| Price to Cash Flow | 33.79 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|